A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.

Front Biosci (Landmark Ed)

Unit of Neuroimmunology and Multiple Sclerosis Center and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Ein-Kerem, 91120 Jerusalem, Israel.

Published: October 2021

: Mesenchymal stem cells (MSC) were shown to induce beneficial effects in animal models of neurodegeneration and in pilot human trials in multiple sclerosis and amyotrophic lateral sclerosis (ALS). : An open-label, clinical trial to evaluate the safety and efficacy of repeated intrathecal administrations of autologous-MSC in ALS-patients. : The study included 20 subjects (age: 20-70) with definite diagnosis of ALS and Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) score of >20. The patients were treated with 1-4 intrathecal injections of MSC, at intervals of 3-6 months. The primary endpoints were safety and tolerability. Efficacy measurements including ALSFRS-R score and forced vital capacity (FVC), were assessed as secondary endpoints. : No serious adverse events were observed during the whole period of the trial. One patient withdrew from the study before the first injection. The monthly rate of progression in ALSFRS-R was ameliorated by more than 25% in 15/19 patients between the 1st and 2nd injection (mean improvement of 107.1%); in 11/12 between the 2nd and 3rd injection and in 8/10 between the 3rd and 4th injection. Overall, during the whole period till the last transplantation 13 patients had a >25% improvement in the slope of progression of ALSFRS-R (mean improvement of 47.4%, < 0.0038, Wilcoxon rank signed test). 7 out of 19 patients actually improved clinically (range of increase in ALSFRS-R: +1 to +4 degrees) after the first transplantation and 5 remained improved after the second cycle. The response rate correlated with the time-intervals between the injections. : The results of our study show that repeated intrathecal injections of autologous MSC was safe in patients with ALS and provide indications of medium-term clinical benefits that were related to the intervals between the administrations of the cells. Larger studies are needed to confirm these observations.

Download full-text PDF

Source
http://dx.doi.org/10.52586/4980DOI Listing

Publication Analysis

Top Keywords

repeated intrathecal
12
intrathecal injections
12
amyotrophic lateral
12
lateral sclerosis
12
clinical trial
8
injections autologous
8
mesenchymal stem
8
stem cells
8
alsfrs-r score
8
progression alsfrs-r
8

Similar Publications

Background: Post-dural puncture headache (PDPH) after an accidental dural puncture (ADP) is a common complication in obstetric analgesia. It has been proposed that inserting an intrathecal catheter (ITC) after an ADP may reduce PDPH incidence and the need for therapeutic epidural blood patch (EBP). Our primary objective was to assess if the insertion of an ITC after an ADP reduces the incidence of PDPH in obstetric patients.

View Article and Find Full Text PDF

Syringable Microcapsules for Sustained, Localized, and Controllable siRNA Delivery.

ACS Appl Mater Interfaces

January 2025

School of Engineering and Applied Sciences (SEAS), Harvard University, Cambridge, Massachusetts 02138, United States.

The clinical use of small interfering RNA (siRNA) and antisense oligonucleotides often requires invasive routes of administration, including intrathecal or intraocular injection. Additionally, these treatments often necessitate repeated injections. While nanoparticle formulation and chemical modifications have extended siRNA therapeutic durability, challenges persist, such as the side effects of bolus injections with high toxicity and maximum exposure in the acute phase.

View Article and Find Full Text PDF

Glucosylceramide synthase inhibitor ameliorates chronic inflammatory pain.

J Pharmacol Sci

December 2024

Laboratory of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo, 108-8641, Japan; Medicinal Research Laboratories, School of Pharmacy, Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo, 108-8641, Japan. Electronic address:

Article Synopsis
  • - Gangliosides are important for functions in nerve cells, influencing processes like growth, communication, and degeneration.
  • - Research indicated that mice given gangliosides made from glucosylceramide experienced heightened sensitivity to touch, known as mechanical allodynia.
  • - The study found that using glucosylceramide inhibitors helped decrease this sensitivity during inflammation in mice, highlighting the potential of targeting gangliosides for pain relief.
View Article and Find Full Text PDF

G(1-5)-EM2, a multi-targeted agonist to opioid and growth hormone secretagogue receptors exhibited nontolerance forming antinociceptive effects in a mouse model of burn pain.

Eur J Pharmacol

January 2025

Department of Physiology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, 330006, PR China; Jiangxi Province Key Laboratory of Brain Science and Brian Health, Nanchang, Jiangxi Province, 330006, PR China. Electronic address:

Burn induced-pain (BIP) is one of the most common pain symptoms, which seriously affects the quality of sufferer life. Researches show that multi-targeted drug therapies offer superior efficacy and fewer side effects compared to single-target drug therapies. Consequently, in this study, we developed G(1-5)-EM2, a multi-targeted peptide designed to target μ-opioid receptor and the growth hormone secretagogue receptor 1α (GHS-R1α), and explored its antinociceptive effects on burn injury pain.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effects of astaxanthin on nociceptive transmission in a mouse model of painful diabetic neuropathy, aiming to assess its potential as a treatment option.
  • Researchers conducted tests with astaxanthin administered through different methods and doses, finding that it effectively reduces hypersensitivity in both male and female mice.
  • The results suggest that astaxanthin not only provides significant analgesic effects on its own but also may enhance pain relief when used with morphine, highlighting its promise for future clinical applications in diabetic neuropathy treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!